Cancer IVD market seen reaching $19.85B by 2030

The cancer in vitro diagnostics market is projected to grow from $15.32 billion in 2026 to $19.85 billion by 2030, according to The Business Research Company. The forecast points to rising cancer rates, more personalized oncology testing and broader use of molecular, genomic and AI-enabled diagnostics.

Why it matters: - Cancer in vitro diagnostics help detect, monitor and guide treatment decisions using blood, tissue and other samples. - The market's growth points to higher demand for earlier cancer detection and more personalized care. - The forecast also signals continued investment in tools that can improve patient outcomes through faster and more precise testing.

What happened: - The Business Research Company projected the cancer in vitro diagnostics market will rise from $14.32 billion in 2025 to $15.32 billion in 2026. - The company forecast the market will reach $19.85 billion by 2030, implying a 6.7% CAGR over the period. - The release was issued Nov. 6, 2026, from London. - The company also made a free sample report available. - The full market report is also available.

The details: - Historical growth has been supported by better hospital diagnostic infrastructure. - Biomarker-based testing adoption has increased. - PCR and immunoassay technologies are in wider use. - Cancer screening programs have expanded. - Laboratory automation has advanced. - The company said future growth will be driven by rising demand for personalized oncology diagnostics. - Other growth factors include investment in genomic sequencing, more point-of-care cancer testing, cloud-based diagnostic platforms and precision medicine. - Key trends expected ahead include more molecular and genomic cancer testing, companion diagnostics, AI-driven data interpretation and liquid biopsy use. - The market's core function is to analyze biomarkers, genetic mutations and other cancer-related indicators. - The diagnostics support early diagnosis, prognosis assessment and treatment selection.

Between the lines: - Rising global cancer incidence remains the biggest demand driver for cancer IVD tools. - An aging population is helping push cancer cases higher as longer life expectancy and lower infectious-disease deaths increase the number of older adults at risk. - The American Cancer Society projected 1,958,310 new cancer cases and 609,820 cancer-related deaths in the U.S. for 2023, underscoring the scale of need. - North America held the largest share of the market in 2025, reflecting strong healthcare infrastructure and diagnostic investment. - Asia-Pacific is projected to be the fastest-growing region in the coming years. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

What's next: - The market is expected to keep expanding as precision medicine and genomic testing become more common. - AI-based interpretation and liquid biopsies could broaden the use of cancer diagnostics. - The report's 2026 updates include TAM analysis, company scoring matrix graphics, Excel forecasting dashboards and market hotspots infographics. - More information is available through the company's LinkedIn page.